Experienced in Plasmacytoma

Dr. Gene G. Finley

Hematology Oncology | Oncology
Allegheny Clinic Medical Oncology
314 E N Ave, Level 1, 
Pittsburgh, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Plasmacytoma
Allegheny Clinic Medical Oncology
314 E N Ave, Level 1, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gene Finley is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Finley is rated as an Experienced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lung Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Independence Health System Butler Memorial Hospita
Allegheny Valley Hospital
Acmh Hospital
Allegheny General Hospital
West Penn Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

ALLEGHENY CLINIC MEDICAL ONCOLOGY
314 E N Ave, Level 1, Pittsburgh, PA 15212
Other Locations
ALLEGHENY CLINIC MEDICAL ONCOLOGY
12311 Perry Hwy, Suite A, Wexford, PA 15090
ALLEGHENY CLINIC MEDICAL ONCOLOGY
1 Nolte Dr, Kittanning, PA 16201
ALLEGHENY CLINIC MEDICAL ONCOLOGY
1301 Carlisle St, Natrona Heights, PA 15065
PHOENIX REHABILITATION AND HEALTH SERVICES INC
2000 Westinghouse Dr, Cranberry Township, PA 16066

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 08, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Relatlimab, Carboplatin, Paclitaxel
Study Phase: Phase 1
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Enrollment Status: Active_not_recruiting
Publish Date: September 27, 2024
Intervention Type: Biological, Drug
Study Drugs: Cetuximab, Irinotecan, Panitumumab, Regorafenib
Study Phase: Phase 2
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Panitumumab, Regorafenib, Trifluridine, Tipiracil
Study Phase: Phase 2
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Enrollment Status: Completed
Publish Date: September 10, 2022
Intervention Type: Drug
Study Drugs: Vopratelimab, Ipilimumab
Study Phase: Phase 2
View 13 Less Clinical Trials

40 Total Publications

Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation.
Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation.
Journal: Case reports in oncological medicine
Published: September 22, 2025
Similar Doctors
Advanced in Plasmacytoma
Dr. Yazan Samhouri
Hematology Oncology | Hematology | Oncology
Advanced in Plasmacytoma
Dr. Yazan Samhouri
Hematology Oncology | Hematology | Oncology

Allegheny Clinic

4815 Liberty Ave, 
Pittsburgh, PA 
 (3.0 miles away)
412-578-4484
Languages Spoken:
English
See accepted insurances

Yazan Samhouri is a Hematologist Oncology specialist and a Hematologist in Pittsburgh, Pennsylvania. Dr. Samhouri is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Plasmacytoma, Burkitt Lymphoma, Non-Hodgkin Lymphoma, Orchiectomy, and Bone Marrow Aspiration.

Experienced in Plasmacytoma
Dr. Stewart L. Lancaster
Hematology Oncology | Oncology
Experienced in Plasmacytoma
Dr. Stewart L. Lancaster
Hematology Oncology | Oncology
605 Sharon Rd, 
Beaver, PA 
 (23.1 miles away)
724-774-0778
Languages Spoken:
English
See accepted insurances

Stewart Lancaster is a Hematologist Oncology specialist and an Oncologist in Beaver, Pennsylvania. Dr. Lancaster is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Multiple Myeloma.

Experienced in Plasmacytoma
Dr. Katerina Ancevski-Hunter
Hematology Oncology | Oncology
Experienced in Plasmacytoma
Dr. Katerina Ancevski-Hunter
Hematology Oncology | Oncology

Upmc/st Clair Hospital Cancer Center

1000 Bower Hill Rd, 
Pittsburgh, PA 
 (6.4 miles away)
412-942-4000
Languages Spoken:
English
See accepted insurances

Katerina Ancevski-Hunter is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Ancevski-Hunter is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Lynch Syndrome, Colorectal Cancer, Familial Colorectal Cancer, and Chromophobe Renal Cell Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Finley's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 99 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile